Literature DB >> 9973519

Determinant spreading associated with demyelination in a nonhuman primate model of multiple sclerosis.

H I McFarland1, A A Lobito, M M Johnson, J T Nyswaner, J A Frank, G R Palardy, N Tresser, C P Genain, J P Mueller, L A Matis, M J Lenardo.   

Abstract

Definition of the immune process that causes demyelination in multiple sclerosis is essential to determine the feasibility of Ag-directed immunotherapy. Using the nonhuman primate, Callithrix jacchus jacchus (common marmoset), we show that immunization with myelin basic protein and proteolipid protein determinants results in clinical disease with significant demyelination. Demyelination was associated with spreading to myelin oligodendrocyte glycoprotein (MOG) determinants that generated anti-MOG serum Abs and Ig deposition in central nervous system white matter lesions. These data associate intermolecular "determinant spreading" with clinical autoimmune disease in primates and raise important issues for the pathogenesis and treatment of multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973519

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Gene-expression profiling of experimental autoimmune encephalomyelitis.

Authors:  Eilhard Mix; Jens Pahnke; Saleh M Ibrahim
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

Review 2.  Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination.

Authors:  H C von Büdingen; N Tanuma; P Villoslada; J C Ouallet; S L Hauser; C P Genain
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

3.  Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis.

Authors:  R K Agarwal; Y Kang; E Zambidis; D W Scott; C C Chan; R R Caspi
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

Review 4.  Experimental autoimmune encephalomyelitis in the common marmoset, a bridge between rodent EAE and multiple sclerosis for immunotherapy development.

Authors:  Yolanda S Kap; Jon D Laman; Bert A 't Hart
Journal:  J Neuroimmune Pharmacol       Date:  2009-10-14       Impact factor: 4.147

5.  Myelin/oligodendrocyte glycoprotein-deficient (MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice.

Authors:  Cécile Delarasse; Philippe Daubas; Lennart T Mars; Csaba Vizler; Tobias Litzenburger; Antonio Iglesias; Jan Bauer; Bruno Della Gaspera; Anna Schubart; Laurence Decker; Dalia Dimitri; Guy Roussel; Andrée Dierich; Sandra Amor; Andre Dautigny; Roland Liblau; Danielle Pham-Dinh
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

Review 6.  Experimental autoimmune encephalomyelitis in the common marmoset: a translationally relevant model for the cause and course of multiple sclerosis.

Authors:  Bert A 't Hart
Journal:  Primate Biol       Date:  2019-05-10

Review 7.  Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases.

Authors:  Christine Riedhammer; Robert Weissert
Journal:  Front Immunol       Date:  2015-06-17       Impact factor: 7.561

8.  The Primate EAE Model Points at EBV-Infected B Cells as a Preferential Therapy Target in Multiple Sclerosis.

Authors:  Bert A 't Hart; S Anwar Jagessar; Krista Haanstra; Ernst Verschoor; Jon D Laman; Yolanda S Kap
Journal:  Front Immunol       Date:  2013-06-13       Impact factor: 7.561

Review 9.  Multiple sclerosis and drug discovery: A work of translation.

Authors:  Bert A 't Hart; Antonio Luchicchi; Geert J Schenk; Joep Killestein; Jeroen J G Geurts
Journal:  EBioMedicine       Date:  2021-05-24       Impact factor: 8.143

Review 10.  Mechanistic underpinning of an inside-out concept for autoimmunity in multiple sclerosis.

Authors:  Bert A 't Hart; Antonio Luchicchi; Geert J Schenk; Peter K Stys; Jeroen J G Geurts
Journal:  Ann Clin Transl Neurol       Date:  2021-06-22       Impact factor: 4.511

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.